Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

2004955 citationsJournal Articlebronze Open Access

Authors

Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding.

Good health and well-being

Published in: Circulation

Volume 110, Issue 7, pp. 874-879

Field-Weighted Citation Impact: 33.34